Czechia· CZ-0222464
BAVENCIO
A avelumab product containing avelumab, registered in Czechia by Merck Europe B.V., Amsterdam. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Avelumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF04 (avelumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Avelumab · ATC L01FF04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- AVELUMAB
- Manufacturer
- Merck Europe B.V., Amsterdam
- Country
- Czechia (CZ)
- ATC code
- L01FF04
- ATC class
- Avelumab
- Defined daily dose
- 57.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02224641X10MLCZK 18986.08
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for avelumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Avelumab · interactions on record
3 records
- 3 severe
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Avelumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBAVENCIOEMD Serono, Inc.
- FinlandBavencioMerck Europe B.V.
- NorwayBavencioMerck Europe B.V.
- IcelandBavencioMerck Europe B.V.*
- BelgiumBavencio 20 mg/mlMerck Europe
- PolandBavencioMerck Europe B.V.
- SwedenBavencio 20 mg/ml Koncentrat till infusionsvätska, lösningMerck Europe B.V.
- IrelandBavencio 20 mg/mL concentrate for solution for infusionMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bavencio
- Liechtenstein · Bavencio
- Norway · Bavencio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0ef6653-29b2-4dca-ba79-df4a4b27e074 GET /v1/drugs/c0ef6653-29b2-4dca-ba79-df4a4b27e074?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF CNC SOL",
"source": "sukl",
"strength": "20MG/ML",
"pack_size": "1X10ML",
"substance": "AVELUMAB",
"cz_kod_sukl": "0222464",
"product_type": "BT",
"substance_codes": "20782",
"registration_state": "R",
"registration_number": "EU/1/17/1214/001"
}See everything about avelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.